The modern biopharmaceutical market is extremely competitive, and manufacturers in this rapidly evolving space are committed to embracing the promise of autonomous bioprocessing: consistent quality, less variability and faster response to change. All these elements help to streamline the path from lab bench to patients, bringing therapeutics to market quicker. However, fully self-directed control is still catching up with regulatory expectations.

The good news? Manufacturers do not have to wait for that finish line to start capturing value.

Hybrid models, which combine mechanistic process understanding with AI and machine learning (ML), are emerging as the most practical way forward. They work with today's regulatory framework rather than against it, delivering measurable benefits well before a plant reaches full autonomy. This approach builds on capabilities many manufacturers already trust — Process Analytical Technology (PAT) for real-time process monitoring and closed-loop control for automated process adjustment, while extending them toward greater autonomy.

What autonomous bioprocess control makes possible

Autonomous bioprocess control — a framework outlined by industry group BioPhorum in a 2025 paper on autonomous control and often shortened to ABC — extends two capabilities most manufacturers already rely on: PAT for real-time process monitoring and closed-loop control for automated process adjustment. It describes a future state where connected unit operations run under one coordinated strategy. Programs, data analytics and process models work together to keep a process within its limits, with minimal human intervention.

Reaching that state offers real advantages. Manufacturers can optimize efficiency across the entire production line rather than one unit operation at a time. And reducing variability becomes easier when models can predict how a change in one step affects the next. What’s more, because the approach builds on quality-by-design principles, it supports regulatory compliance across the full product lifecycle, from early development through commercial manufacturing.

None of this happens overnight, and, frankly, it doesn’t need to. That’s where hybrid models come in.

Why hybrid models are the practical starting point

A hybrid model earns its name by pairing mechanistic knowledge of a process with AI and ML capabilities. It builds on the same real-time measurement principles established by PAT, extending them into predictive, closed-loop decision-making. This combination lets manufacturers make efficient use of the smaller datasets typical of early development, while still building toward the larger, more automated systems needed at commercial scale.

Hybrid models evolve alongside the processes they support. Early on, a model functions as a digital prototype, demonstrating basic capability in a sandbox environment. As it is tested against real conditions, it becomes a digital shadow, verifying that it aligns with reality. Once validated, it becomes a predictive twin, useful for in-silico work that reduces the need for physical materials.

In commercial manufacturing, a proven model can operate as an autonomous twin, maintaining control over variable inputs while staying in continuous learning mode. This staged evolution matters because it means manufacturers do not need one giant leap to autonomy. Each stage delivers its own value, and each one builds the case and the data needed for the next.

Where gaps remain

Full-scale adoption of ABC faces real gaps and naming them plainly helps manufacturers plan around them rather than be surprised by them:

• Data remains the biggest hurdle. Many facilities still work with fragmented systems and inconsistent data standards, which makes real-time analytics harder than it should be.
• Validation frameworks for autonomous and self-learning processes are also still maturing, alongside regulatory guidance on how AI-driven decisions get accepted.
• Workforce readiness deserves real attention: building and evaluating hybrid models requires people who understand the process science and the data science, and that combination is not yet common.

These gaps mark where the next round of collaborative work between manufacturers, technology providers and regulators needs to happen.

Five steps toward autonomous control

Manufacturers can make steady progress by focusing on five interdependent areas:

• Build an Industrial DataOps foundation. Connect, contextualize and govern data from equipment, processes, materials, quality systems and facilities so manufacturers can create a trusted, reusable flow of operational information. This foundation turns fragmented raw data into context-rich insights that support real-time decisions, scalable AI and analytics.
• Develop a comprehensive control strategy. Use in-silico models to test control strategies in a sandbox environment before committing to large-scale batches and design control outputs around critical quality attributes.
• Design a validation methodology. Build systematic approaches for validating digital models, including corrective and preventive actions and align these with existing process validation frameworks.
• Orchestrate process integration. Identify the parameters that affect the entire process, not just one unit operation, and incorporate digital twins and predictive models to validate outcomes and anticipate deviations.
• Plan for regulatory alignment from the start. Design control strategies and monitoring systems around a regulatory landscape that is becoming more digital, data-driven and lifecycle-oriented — including FDA Remote Regulatory Assessments and KASA, EMA’s expanded use of real-world data and digital evidence, NMPA’s revised medical device GMP requirements effective November 2026, and emerging expectations for AI governance, data transparency, cybersecurity and advanced manufacturing. This means building systems that can support electronic records requests, inspection-ready evidence, validated models, human oversight and ongoing lifecycle monitoring as guidance continues to evolve.

These steps depend on each other. A data foundation without a validation methodology will not hold up under scrutiny, and a control strategy without regulatory planning will struggle to reach commercial deployment. Treating them as a connected sequence, rather than a checklist, gives manufacturers the best chance of steady progress.

Progress without waiting for perfection

The path to autonomous bioprocess control does not require manufacturers to solve every gap before starting. Hybrid models let organizations build capability in phases, gaining real value at each stage while staying aligned with regulatory expectations. For manufacturers already invested in PAT and closed-loop control, this represents a natural evolution rather than a wholesale change in strategy.

As the industry continues to refine data standards, validation frameworks and workforce skills, manufacturers that start now, with a phased and well-grounded approach, will be best positioned to benefit as the technology and the regulatory landscape mature together.